Skip Navigation

European Heart Journal 2002 23(17):1322-1323; doi:10.1053/euhj.2002.3225
Copyright © 2002 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Doughty, R.N.
Right arrow Articles by Sharpe, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Doughty, R.N.
Right arrow Articles by Sharpe, N.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Editorials

Optimization of ACE inhibitor therapy in heart failure

R.N. Doughty and N. Sharpe

Division of Medicine, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand

References

  1. Cowley AJ, Skene AM. Treatment of severe heart failure: quantity or quality of life? A trial of enoximone. Br Heart J. 1994;72:226–230[Abstract/Free Full Text]
  2. Packer M, Carver JR, Rodeheffer RJ. Effect of oral milrinone on mortality in severe heart failure. N Engl J Med. 1991;325:1468–1475[Abstract]
  3. Cooke GA, Williams SG, Marshall P. A mechanistic investigation of ACE inhibitor dose effects on aerobic exercise capacity in heart failure patients. Eur Heart J. 2002;23:1358–1366
  4. Tang WHW, Vagelos RH, Yee Y-G. Neurohormonal and clinical responses to high-versus low-dose enalapril therapy in chronic heart failure. J Am Coll Cardiol. 2002;39:70–78[Abstract/Free Full Text]
  5. Packer M, Poole-Wilson Armstrong PW. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation. 1999;100:2312–2318[Abstract/Free Full Text]
  6. N Engl J Med. 1987;316:1429–1435[Abstract]
  7. N Engl J Med. 1991;325:293–302[Abstract]
  8. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (n-BNP) concentrations. Lancet. 2000;355:1126–1130[CrossRef][ISI][Medline]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Doughty, R.N.
Right arrow Articles by Sharpe, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Doughty, R.N.
Right arrow Articles by Sharpe, N.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?